Cardiovascular

Latest News
June 19th 2025

40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death

June 3rd 2025

Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease

May 23rd 2025

CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

May 14th 2025

3 Maternal Risk Factors Linked to Elevated Offspring Blood Pressure

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

AJMC Peer Exchange logo
Video Interviews
View All
July 1st 2025

GME Funding Is Crucial to Addressing the Physician Shortage: Merrill Stewart, MD

June 26th 2025

Using Video Education to Boost Patient Engagement in Echocardiography: Merrill Stewart, MD

June 18th 2025

Cost and Infrastructure Slow Cardiac PET Adoption: Merrill Stewart, MD

June 9th 2025

Not All Coronary Blockages Need Fixing: Merrill Stewart, MD

June 3rd 2025

How Can PET Cardiac Stress Testing Prevent Invasive Procedures? Merrill Stewart, MD

May 12th 2025

Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

May 12th 2025

Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

May 12th 2025

Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

May 6th 2025

Technological Advances in CV Care Depend on Human Resources: Antoine Keller, MD

May 5th 2025

Lp(a) Testing: Prevalence and Strategies to Improve Uptake

Podcasts
View All
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

February 22nd 2020

Podcast: This Week in Managed Care—Setbacks for Medicaid Work Rules and Other Health News

June 2nd 2019

Podcast: This Week in Managed Care—The $2 Million Gene Therapy and Other Health News

December 1st 2018

Podcast: This Week in Managed Care—CMS Drug Coverage Changes Draw Ire and Other Health News

November 18th 2018

Podcast: This Week in Managed Care—Cancer Is the New Leading Cause of Death and Other Health News

November 10th 2018

Podcast: This Week in Managed Care—Medicaid Expansion at the Ballot Box and Other Health News

June 17th 2017

Podcast: This Week in Managed Care - Dropped ACA Coverage, and Other News

Continuing Medical Education
View All
July 2nd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 2nd 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology
July 2nd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
July 2nd 2025

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology
July 2nd 2025

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Cardiology, Rare Diseases
July 2nd 2025

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

More News

Nurse using stethoscope on older patient | Image credit: InsideCreativeHouse – stock.adobe.com
May 9th 2025

Is Frailty Index the Most Accurate Predictor of CVD?

Hayden E. Klein
A study comparing biological aging indicators found that Rockwood Frailty Index was a stronger predictor of cardiovascular disease (CVD) than leukocyte telomere length in adults without prior CVD.
Antoine Keller, MD
May 9th 2025

Striving for Health Equity: Antoine Keller, MD

Kyle Munz Antoine Keller, MD, FACC, FACS
Antoine Keller, MD, argued the value of grounding health care policy in equity as clinicians prepare for a changing health care landscape in the coming years.
Effect of Remote Patient Monitoring on Stage 2 Hypertension
May 6th 2025

Effect of Remote Patient Monitoring on Stage 2 Hypertension

Lyle Dennis, MD Irina Koyfman, DNP, NP-C, RN
A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential benefits of RPM with care coaching.
Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment
May 5th 2025

Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss how knowledge of lipoprotein(a) (Lp[a]) levels can empower patients in managing atherosclerotic cardiovascular disease (ASCVD) risk factors, how providers can collaborate with patients on Lp(a) testing and risk management, the potential population-level value of improved ASCVD risk assessment, and how the National Lipid Association’s (NLA) recommendation for one-time Lp(a) testing may benefit health systems.
The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
April 28th 2025

The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss how lipoprotein(a) (Lp[a]) testing, even without targeted Lp(a)-lowering therapies, can enhance overall cardiovascular risk assessment and potentially influence the management of other risk factors.
FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels
April 28th 2025

FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss FDA-approved therapies for high lipoprotein(a) [Lp[a]) levels, their benefits and shortcomings, the frequency of their use in health plans, emerging therapies in the pipeline, and the expected timeline for associated data release.
Q&A with Sid Patel, MD
April 24th 2025

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

Kyle Munz Siddharth M. Patel, MD, MPH
The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.
Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing
April 21st 2025

Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the cost of lipoprotein(a) (Lp[a]) tests and how these costs, along with the National Lipid Association’s (NLA) recommendation and supporting clinical evidence, may influence payer decisions regarding coverage for Lp(a) testing.
Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
April 21st 2025

Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss whether providers should wait for another complete scientific statement from the National Lipid Association (NLA) or new guidelines from organizations like the American Heart Association (AHA) before implementing the 2024 NLA recommendation for universal lipoprotein(a) (Lp[a]) measurement.
One's ZIP code can greatly influence care access | image credit: Syda Productions - stock.adobe.com
April 18th 2025

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

Kyle Munz Antoine Keller, MD, FACC, FACS
Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Evidence Supporting 2024 Guidance for Lp(a) Testing
April 14th 2025

Evidence Supporting 2024 Guidance for Lp(a) Testing

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the evidence supporting the National Lipid Association’s (NLA) recommendation for universal lipoprotein(a) (Lp[a]) measurement and evaluate how compelling this evidence is from a clinical perspective.
The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations
April 14th 2025

The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss how guideline recommendations influence formulary decisions regarding preventive measures like lipoprotein(a) (Lp[a]) testing, exploring the varying recommendations from organizations such as the American Association of Clinical Endocrinologists, the American Heart Association, and the National Lipid Association (NLA), and how these align with recent guidance from Europe and Canada.
Joseph Saseen, PharmD
April 10th 2025

Lp(a) Awareness Imperative for Enhancing Testing, Prevention Efforts in CVD: Joseph Saseen, PharmD

Kyle Munz Joseph J. Saseen, PharmD
Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the best patient care and spread awareness to those who might be affected.
Jeremy Wigginton, MD
April 8th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

Kyle Munz Jeremy Wigginton, MD
Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
April 7th 2025

A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss an example illustrating the association between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk and explore how this example can inform our understanding of Lp(a) and ASCVD risk on a population level.
How the Genetic Nature of Lp(a) Levels Influences Screening
April 7th 2025

How the Genetic Nature of Lp(a) Levels Influences Screening

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the genetic determinants of lipoprotein(a) (Lp[a]) levels, providing evidence supporting this conclusion. They also explore how the hereditary nature of Lp(a) can drive awareness of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis risk, potentially influencing screening protocols.
ACC.25
April 4th 2025

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

Giuliana Grossi Christian Ruff, MD John Buse, MD, PhD Marc P. Bonaca, MD, MPH Marc Humbert, MD, PhD Jawad Haider Butt, MD, PhD Siddharth M. Patel, MD, MPH
Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Heart disease is, and has been, the number 1 cause of death for Americans over the last century | image credit: Thirakun - stock.adobe.com
April 2nd 2025

Digital Solutions Can Transform CVD Care, Prevention

Kyle Munz
Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to manage and prevent heart disease.
Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
March 31st 2025

Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the evidence supporting the continuous relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD), as recognized by the National Lipid Association, and explore how Lp(a) levels may change throughout a person’s lifetime or in response to lifestyle factors.
Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
March 31st 2025

Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk, with findings from a large US population study, and explore how these findings could impact clinical practice and the management of patients at risk for ASCVD.
Jaime Murillo, MD
March 29th 2025

AI Is Changing the Landscape of Cardiovascular Care

Kyle Munz Jaime Murillo, MD
Implementing artificial intelligence (AI) has transformed clinicians' and health systems' ability to screen for and distinguish forms of cardiorenalmetabolic disease.
Improving Cardiovascular Treatment Adherence Through Education, Engagement
March 26th 2025

Improving Cardiovascular Treatment Adherence Through Education, Engagement

Kyle Munz Jaime Murillo, MD
Jaime Murillo, MD, discusses the importance of fostering open communication with patients as a means of encouraging adherence to various treatments.
Nathan Wong, PhD
March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD
Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.
The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
March 24th 2025

The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the clinical and economic burden of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis in the US, exploring their impact on health care systems, the importance of prevention in reducing this burden, and the challenges of implementing preventive strategies, while considering the potential benefits of improved risk assessment and prevention in the ASCVD space.
Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
March 24th 2025

Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss atherosclerotic cardiovascular disease and aortic stenosis, as well as their burden, highlighting their prevalence, impact on patient health, and the growing need for effective management strategies.
FDA Approval | image credit: PKartstudio - stock.adobe.com
March 21st 2025

FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions

Kyle Munz
In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Nihar Desai, MD, MPH
March 20th 2025

PROMPT Trials, Electronic Alerts, and Enhancing CV Outcomes

Kyle Munz Nihar Desai, MD, MPH
The PROMPT trials evaluate the influence of electronic health alerts for informing appropriate, evidence-based therapies to patients with cardiovascular conditions.
Tom Belmont
March 17th 2025

2025 GPBCH Employer Symposia Set to Address Cardiovascular, MSK Challenges

Kyle Munz Tom Belmont
Tom Belmont, president and CEO, Greater Philadelphia Business Coalition on Health (GPBCH) previews the upcoming employer symposia, which seeks to help employers navigate solutions for the management and prevention of cardiovascular and musculoskeletal disease.
Semaglutide. | Image Credit: K KStock - stock.adobe.com
March 14th 2025

Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive

Cameron Santoro
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.
Dallas Texas | Image Credit: © SeanPavonePhoto - stock.adobe.com
March 13th 2025

Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most

Christina Mattina
On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
12345678
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo